Physician profile
Monica E Wideman
NPI 1750621207
$1,926.52
in general payments reported to CMS, 2019-2025
13 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.09 · 2022: $367 · 2023: $407 · 2024: $724 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $308.51 | 2023-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $252.61 | 2022-2024 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $236.15 | 2023-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $229.41 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $199.32 | 2021-2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $161.10 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2025 | Rexulti |
| Gilead Sciences, INC. | $124.99 | 2024 | Epclusa |
| Abbvie INC. | $108.97 | 2024 | |
| Mylan Specialty L.P. | $104.26 | 2022 | |
| Lundbeck LLC | $30.07 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.74 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.40 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Wideman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.